Willow Biosciences (TSX: WLLW) (OTCQX: CANSF) today announced its completion of the first commercial scale fermentation run of its first cannabinoid for market, cannabigerol (“CBG”). “We are very pleased with the yield and quality of our first commercial scale fermentation run of CBG,” said Trevor Peters, Willow’s president and chief executive officer. “I think it is important to take a moment to reflect on all that we have achieved in just under two years as a public company. In this time, we built a world class industrial R&D team, demonstrated proof of concept for production of cannabinoids through fermentation, attracted reputable development partners like Albany Molecular Research Inc., and produced our first commercial scale batch of CBG. On the capital markets side, we have completed three successful financings bringing in supportive and sophisticated shareholders who have provided us with a healthy balance sheet to execute on our business plan. We are now starting the next phase of Willow’s lifecycle, which will involve supplying commercial quantities of cannabinoids to customers and recognizing revenue therefrom.”
To view the full press release, visit https://cnw.fm/HgIyk
About Willow Biosciences Inc.
Willow is a Canadian biotechnology company based in Vancouver, British Columbia that produces high-purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow’s current focus is in the production of cannabinoids for the treatment for pain, anxiety, obesity, brain disorders, among other significant indications. Willow’s science team has a proven track record of developing manufacturing technologies for high-purity compounds in pain and cancer treatments. Willow’s manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life-changing drugs. For more information, visit the company’s website at www.WillowBio.com.
NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://cnw.fm/WLLW
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire is part of the InvestorBrandNetwork.